Latest Period
Q1 2026
Security Snapshot
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) Institutional Ownership
CUSIP: 82835W108
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
200
Shares (Excl. Options)
94,099,513
Price
$8.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- SPRY on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 94,099,513
- Total 13F value
- $755,807,496
- Portfolio coverage rank
- 0%
- Share change
- +3,913,561
- Value change
- +$10,864,887
- Number of holders
- 200
- Shares outstanding
- 98,457,811
- SEC-reported price per share
- $7.74
- Insider filing price
- $7.74
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SPRY - ARS Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 82835W108.
- 200 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 200 to 68 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $755,807,496 to $168,242,813.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 200 institutions filings for Q1 2026.
Security key
82835W108
Latest holder period
Q1 2026
13F holders
200
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
SPRY full holder history
ARS Pharmaceuticals, Inc. SEC filings
ARS Pharmaceuticals, Inc. company facts
ARS Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 82835W108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
SPRY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | $111,050,917 | 10,940,977 | RA Capital Management, L.P. | 29 Sep 2025 | |||
| Rubric Capital Management LP | 8.1% | +30% | $64,400,000 | +$14,490,000 | 8,000,000 | +29% | Rubric Capital Management LP | 31 Mar 2026 |
| Flynn James E | 7.8% | -12% | $134,624,739 | -$18,102,531 | 7,610,217 | -12% | Deerfield Management Company, L.P. | 30 Jul 2025 |
| BlackRock, Inc. | 5.3% | +6.4% | $41,798,295 | +$2,177,535 | 5,218,264 | +5.5% | BlackRock, Inc. | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC | 2.5% | -58% | $20,192,705 | -$27,194,695 | 2,520,937 | -57% | Millennium Management LLC | 30 Jun 2026 |
As of 31 Mar 2026, 200 institutional investors reported holding 94,099,513 shares of ARS Pharmaceuticals, Inc. - Common Stock (SPRY). This represents 96% of the company’s total 98,457,811 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
82%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 10,860,977 | 0% | 0.92% | $87,213,645 |
| ORBIMED ADVISORS LLC | 8.4% | 8,288,510 | 0% | 1.5% | $66,556,735 |
| Rubric Capital Management LP | 8.1% | 8,000,000 | +29% | 0.79% | $64,240,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.6% | 7,503,812 | 0% | 0.71% | $60,255,610 |
| MILLENNIUM MANAGEMENT LLC | 6.1% | 5,982,919 | +89% | 0.04% | $48,042,840 |
| BlackRock, Inc. | 5.1% | 5,012,254 | -1.4% | 0% | $40,248,399 |
| Aberdeen Group plc | 4.2% | 4,113,617 | +16% | 0.05% | $33,032,345 |
| SR One Capital Management, LP | 4.1% | 4,012,903 | 0% | 3.5% | $32,223,611 |
| STATE STREET CORP | 3.7% | 3,644,966 | +13% | 0% | $29,269,077 |
| FRANKLIN RESOURCES INC | 3.3% | 3,278,549 | +29% | 0.01% | $26,326,745 |
| Tyro Capital Management LLC | 3% | 2,968,599 | +49% | 6% | $23,837,850 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 2,542,504 | 0% | 0% | $20,416,307 |
| UBS Group AG | 2.3% | 2,260,325 | +2.2% | 0% | $18,150,410 |
| Janney Montgomery Scott LLC | 2% | 2,016,464 | +57% | 0.04% | $16,192,000 |
| CITADEL ADVISORS LLC | 1.8% | 1,773,188 | -9.3% | 0.01% | $14,238,699 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,526,824 | -1.7% | 0% | $12,263,317 |
| ADAR1 Capital Management, LLC | 1.4% | 1,361,536 | +268% | 0.66% | $10,933,134 |
| BAMCO INC /NY/ | 1.3% | 1,273,341 | +0.38% | 0.03% | $10,224,928 |
| Third Point LLC | 1% | 1,000,000 | +80% | 0.39% | $8,030,000 |
| GENERAL AMERICAN INVESTORS CO INC | 0.74% | 727,154 | +30% | 0.39% | $5,839,047 |
| GOLDMAN SACHS GROUP INC | 0.74% | 724,219 | -11% | 0% | $5,815,478 |
| Nextech Invest, Ltd. | 0.62% | 610,703 | -7.6% | 0.35% | $4,903,945 |
| Pavaki Capital Management LLC | 0.59% | 576,200 | -51% | 3.3% | $4,626,886 |
| K2 PRINCIPAL FUND, L.P. | 0.57% | 559,697 | +5387% | 0.68% | $4,494,367 |
| LEVIN CAPITAL STRATEGIES, L.P. | 0.56% | 552,561 | -26% | 0.34% | $4,437,065 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 21,004,265 | $168,242,813 | +$11,719,108 | $8.01 | 68 |
| 2026 Q1 | 94,099,513 | $755,807,496 | +$10,864,887 | $8.03 | 200 |
| 2025 Q4 | 88,986,229 | $1,036,491,649 | +$65,098,685 | $11.65 | 189 |
| 2025 Q3 | 83,632,743 | $840,434,931 | -$93,311,095 | $10.05 | 187 |
| 2025 Q2 | 84,521,210 | $1,475,027,148 | +$149,943,852 | $17.45 | 185 |
| 2025 Q1 | 76,226,291 | $958,937,759 | +$63,838,841 | $12.58 | 182 |
| 2024 Q4 | 71,304,827 | $752,320,202 | +$68,074,351 | $10.55 | 163 |
| 2024 Q3 | 63,765,651 | $925,913,322 | +$31,092,478 | $14.50 | 148 |
| 2024 Q2 | 62,590,275 | $533,041,807 | +$21,909,612 | $8.51 | 112 |
| 2024 Q1 | 59,892,345 | $612,088,771 | -$16,199,586 | $10.22 | 113 |
| 2023 Q4 | 65,423,068 | $358,517,051 | -$2,784,476 | $5.48 | 99 |
| 2023 Q3 | 66,524,840 | $251,464,826 | +$38,754,815 | $3.78 | 94 |
| 2023 Q2 | 55,071,412 | $368,976,724 | +$11,246,123 | $6.70 | 92 |
| 2023 Q1 | 53,405,274 | $347,669,060 | +$19,586,591 | $6.51 | 88 |
| 2022 Q4 | 50,164,476 | $427,856,540 | +$173,112,031 | $8.53 | 72 |
| 2022 Q3 | 30,422,972 | $160,377,408 | +$24,492,078 | $5.28 | 58 |
| 2022 Q2 | 26,061,019 | $110,514,000 | -$387,734 | $4.24 | 60 |
| 2022 Q1 | 26,983,988 | $94,707,000 | -$19,556,342 | $3.51 | 66 |
| 2021 Q4 | 30,103,833 | $200,460,000 | -$13,223,479 | $6.66 | 71 |
| 2021 Q3 | 28,894,700 | $288,363,500 | -$42,490,899 | $9.98 | 73 |
| 2021 Q2 | 27,989,545 | $864,603,729 | +$5,243,899 | $30.89 | 74 |
| 2021 Q1 | 27,691,694 | $1,205,836,321 | +$139,058,596 | $43.63 | 67 |
| 2020 Q4 | 24,444,347 | $1,127,544,026 | +$1,117,084,030 | $46.34 | 61 |